Exploitation of EMT regulatory proteins as distinct phenotypic markers of tumor progression, as well as novel therapeutic targets including cellular processes mediated by the TGF-β non-SMAD signaling family that facilitate a tumor-promoting microenvironment, will lead to precision diagnosis and optimized combination strategies to impair metastatic and therapeutically resistant disease. The gene discussed is TGFB1; the disease is neoplasm.